MFDS
- Status: likely_approved
🇰🇷 Reyvow in South Korea
Reyvow (LASMIDITAN) regulatory status in South Korea.
Marketing authorisation
Reyvow in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Neuroscience approved in South Korea
Frequently asked questions
Is Reyvow approved in South Korea?
Yes. MFDS has authorised it.
Who is the marketing authorisation holder for Reyvow in South Korea?
Eli Lilly is the originator. The local marketing authorisation holder may differ — check the official source linked above.